Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

Benjamin Z. Leder, Carol Zapalowski, Ming Yi Hu, Gary Hattersley, Nancy E Lane, Andrea J. Singer, Robin K. Dore

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences